The pharmacological management of depression by Kupfer, David J.
epressive disorders are common, recurrent,
chronic,and require treatment.Major depressive disor-
der can occur across the entire life cycle and is the most
common of the severe psychiatric illnesses.In the USA,
the lifetime prevalence was 16.2% (32.6-35.1 million
adults) and the 12-month prevalence was 6.6% (13.1-
14.2 million adults) in a recent survey.
1According to the
World Health Organization’s Global Burden of Disease
Report,
2 major depression was the fourth leading cause
of disease burden worldwide in 1990.The World Health
Organization predicts that by 2020,major depression will
become the second leading cause of worldwide disease
burden,surpassed only by ischemic heart disease.In this
review, we will focus on major depressive disorder,
although we will also briefly discuss bipolar depression.
Symptom picture syndrome
The cardinal feature of major depression is persistent
depressed mood or pervasive loss of interest or pleasure
for a minimum of 2 weeks, accompanied by a series of
somatic and cognitive changes (Table I). In assessing the
core components of depression,it is important to note that
the psychological and biological symptoms are accompa-
nied by negative thought content,cognitive dysfunction,
and suicidal ideation. These components follow the
American Psychiatric Association Diagnostic and Statisti-
cal Manual of Mental Disorders (DSM-IV) nosology for
mood disorders,but recently there has been considerable
interest in assessing not only current symptoms,but also
“softer”or spectrum features,which may present lifetime
signs of particular mood or mood-related spectra.
3,4 In fact,
such persistent features may relate to levels of functional
impairment during episodes of depression more directly
than current symptoms.Such assessment strategies raise
the need for assessment of dimensional approaches to
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Depressive disorders are common, recurrent, and chronic,
and require treatment. A review of the symptom picture
and current drug targets demonstrates the need for accu-
rate assessment of depression severity, including suicidal-
ity. The initial focus of treatment is rapid resolution of
symptoms during an acute phase, followed by continua-
tion. Maintenance treatment is indicated if the risk of
recurrence is high. The range of available medications is
considerable and the benefit/risk ratio is acceptable.
Depression is diagnosable across the life span and treat-
able at every age (although recent disagreement has
arisen with regard to young patients). Comorbidity, both
psychiatric and medical, need to be assessed, as does the
possible presence of two subtypes of depression (psychotic
and bipolar) often requiring different interventions. It is
expected that the next generation of antidepressants
would be associated with more specific disease and out-
come biomarkers.  
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(e-mail: kupferdj@upmc.edu)diagnosis,as well as the measurement of traditional cate-
gorical distinctions.
5Women are at twice the risk of men.
Depression can and often does co-occur with another psy-
chiatric condition or with a medical disease.Depression is
a life-threatening illness for both men and women since
suicide is estimated to be the cause of death in up to 6%
of individuals with clinical depression.
6
Pathogenesis and drug targets
It has been assumed that the neurobiological systems
involved in the pathogenesis of depression are primarily
the monoaminergic neurotransmitter systems.Considerable
research has been directed toward  uncovering  specific
defects in serotonin (5-hydroxytryptamine [5-HT]),nor-
epinephrine (NE),and to a lesser extent dopamine (DA)
neurotransmitter systems.The blockade of neurotrans-
mitter receptors or transporters by antidepressant drugs
occurs at the level of the neuronal synapse.This capac-
ity to produce acute increases in synaptic levels of
monoamines (Table II)
7 has been long considered respon-
sible for both therapeutic and adverse effects of antide-
pressants.However,recent advances in the neuroscience
of mood regulation have pointed to the involvement of
additional neurotransmitter systems and to the influence
of several neuroendocrine axes;however,these discover-
ies have not yet led to approved treatments for depression,
nor have they fundamentally changed our basic under-
standing of depression.Further developments in the drug
treatment of depression are being actively pursued.
Medications currently under testing programs include dual
reuptake inhibitors,novel dopamine reuptake inhibitors,
drugs combining 5-HT reuptake inhibition with 5-HT2/
5-HT3 receptor antagonism,corticotropin-releasing factor
(CRF) receptor antagonists, substance P (neurokinin)
receptor antagonists, melatonergic agonists, and com-
pounds modulating glutamatergic neurotransmission.
Other novel treatment strategies are also in the pipeline.
8
Most recently, attention has moved from intrasynaptic
changes in neurotransmitter levels to changes in intracel-
lular signaling pathways.
9 In an important review,Manji
and colleagues
9 raise the possibility that depression may
be associated with impairments in signaling pathways that
are considered important for the regulation of neuroplas-
ticity and cell survival. The heuristic value of such an
approach,as highlighted in Figure 1,points to the wide-
ranging possibilities of understanding the mechanisms of
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Selected abbreviations and acronyms
CBT cognitive behavioral therapy
DA dopamine
5-HT 5-hydroxytryptamine (serotonin)
MAOI monoamine oxidase inhibitor
NE norepinephrine
NNT number needed to treat
SNRI serotonin and noradrenaline uptake inhibitor
SSRI selective serotonin reuptake inhibitor
TCA tricyclic antidepressant
Table I. Core components of major depression.
Depressed mood or sadness Negative thought content
Loss of interest (motivation) • Guilt/self-blame
Loss of libido • Worthlessness
Inability to enjoy oneself • Low self-esteem
Irritability • Pessimism 
Anxiety • Hopelessness
Changes in sleep Cognitive dysfunction
Changes in appetite • Diminished decision-making 
Changes in energy ability
Psychomotor retardation • Poor memory
• Poor concentration
Suicidal ideation
Table II. Antidepressant potency for blocking norepinephrine (NE), serotonin
(5-hydroxytryptamine [5-HT]), and dopamine (DA) transporters.  +
to +++++, increasing levels of potency; -, weak; 0, no effect.
Adapted from reference 7: Richelson E. The clinical relevance of antide-
pressant interaction with neurotransmitter transporters and receptors.
Psychopharmacol Bull. 2002;36:133-149. Copyright © 2002. Medworks
Media LLC.
Antidepressant NE 5-HT DA
Amitriptyline +++ ++++ -
Amoxapine +++ +++ -
Bupropion 0 - +
Citalopram - +++++ 0
Clomipramine +++ ++++++ -
Desipramine +++++ +++ -
Doxepin +++ +++ 0
Duloxetine ++++ ++++++ +
Fluoxetine ++ +++++ -
Fluvoxamine + +++++ -
Imipramine +++ +++++ -
Mirtazapine - 0 0
Nefazodone ++ ++ ++
Paroxetine +++ ++++++ +
Sertraline + ++++++ +++
Venlafaxine + ++++ -The pharmacological management of depression - Kupfer Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
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Figure 1. Neuroplasticity and cellular resilience in mood disorders: the multiple influences on neuroplasticity and cellular resilience in mood disor-
ders. Genetic/neurodevelopmental factors, repeated affective episodes, and illness progression might all contribute to the impairments of
cellular resilience, volumetric reductions, and cell death/atrophy observed in mood disorders. Stress and depression likely contribute to
impairments of cellular resilience by a variety of mechanisms, including reductions in the levels of brain-derived neurotrophic factor (BDNF),
facilitating glutamatergic transmission via N-methyl-D-aspartate (NMDA) and nonNMDA receptors, and reducing the cells energy capac-
ity. Neurotrophic factors, such as BDNF, enhance cell survival by activating two distinct signaling pathways: the phosphatidylinositol (PI)-
3-kinase pathway, and the extracellular signal–regulated kinase (ERK)-mitogen activated protein (MAP)-kinase pathway. One of the major
mechanisms by which BDNF promotes cell survival is by increasing the expression of the major cytoprotective protein, BcI-2. BcI-2 atten-
uates cell death via a variety of mechanisms, including impairing the release of calcium and cytochrome c, sequestering proforms of death-
inducing capase enzymes, and enhancing mitochondrial calcium uptake. The chronic administration of a variety of antidepressants increases
the expression of BDNF, and its tyrosine kinase receptor (trkB). Lithium and valproic acid (VPA) robustly upregulate the cytoprotective pro-
tein BcI-2. Lithium and VPA also inhibit glucogen synthase kinase (GSK-3b), biochemical effects shown to have neuroprotective effects.
VPA also activates the ERK-MAP-kinase pathway, effects that may play a major role in neurotrophic effects and neurite outgrowth. NGF,
nerve growth factor; BcI-2 and BcI-x, antiapoptotic members of the BcI-2 family; BAD and Bax, proapoptotic members of the BcI-2 fam-
ily; Ras, GTP, Raf, MEK, ERK, components of the ERK-MAP-kinase pathway; CREB, cyclic adenosine monophosphate (cAMP) responsive
element binding protein; Rsk-2, ribosomal S-6 kinase; ROS, reactive oxygen species; GR, glucocorticoid receptor; 5-HT, 5-hydroxytrypt-
amine; NE, norepinephrine; P, phosphorylation.
Reproduced with permission from reference 9: Manji HK, Drevets WC, Charney DS. The cellular neurobiology of depression. Nat Med. 2001;7:541-547.
Copyright © 2001 Nature Publishing Group.
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Bcl-2action of currently available medications,but raise the pos-
sibilities of new targets for future drug development.
Furthermore,the review proposes roles for chronic stress.
In turn,McEwen’s concept of “allostatic load”may be incor-
porated into how recurrent depression leads to structural
and functional central nervous system (CNS) impairment.
10
Assessment
In assessing depression,clinicians should consider the level
of symptom severity and current functional impairment of
the patient,the duration of the depression,the presence of
psychotic symptoms,level of suicidality,and previous ill-
ness and treatment history.Most depressed patients do not
self-refer directly to a psychiatrist.Instead,they seek help
from a primary care physician,often focusing on somatic
disorders or energy rather than mood complaints.
Recognition (sometimes more difficult in men) and appro-
priate diagnosis should be followed immediately by a
treatment plan. If the plan includes medication, it must
involve the choice of an appropriate drug prescribed at an
adequate dosage and for a sufficient duration,with atten-
tion to treatment adherence by patient and family mem-
bers or caretakers,if necessary.
11 Recognition and treat-
ment of depression in the context of an ongoing medical
disease,such as diabetes or hypertension,is very impor-
tant.The primary care physician is generally in an excel-
lent position to do so if he or she is responsible for the
overall medical care of the patient.Consultation and refer-
ral to a psychiatrist is appropriate in selected cases if the
primary care physician is concerned about the complexity
of the case.The treating physician needs to evaluate the
complexity of the symptom picture (eg,delusions,mixed
manic and depressive symptoms) and dangerousness with
respect to suicide or homicide at each visit. He or she
should seek consultation in difficult-to-treat cases.Several
forms of brief depression-specific psychotherapy,includ-
ing cognitive therapy
12 and interpersonal psychotherapy,
13,14
have been shown to have efficacy equal to that of antide-
pressant medication and should be considered as treat-
ment options or adjuncts.However,a review of these treat-
ment strategies is beyond the scope of this review.
Assessment of suicidality
Probably half of patients with major depressive episodes
report death wishes,feeling that they have no reason to
live,thinking they would be better off dead,thoughts of
harming or killing themselves, or actual plans to do so.
Suicidal risk should be assessed not only at the initiation
of treatment,but repeatedly throughout treatment.Some
patients will not report suicidal ideation until they feel
comfortable with the clinician,often several weeks into
treatment.It is essential to ask if patients have thoughts or
plans to harm themselves,whether they have a history of
suicide attempts (and,if so,to determine the medical seri-
ousness of prior attempts),and whether they have access
to means.This includes specific questions about access to
firearms,since half of all suicides in the USA involve hand-
guns.
15 If a patient acknowledges a plan or intent to harm
him/herself,then emergency psychiatric evaluation is indi-
cated.Up to 75% of patients who complete suicide
15 have
seen a primary care physician within the month prior to
death,meaning that the physician has a unique opportu-
nity to prevent suicide through appropriate intervention.
Depressed patients with suicidal ideation often take longer
to respond to treatment,thus necessitating a longer period
of vigilance on the clinician’s part.
16 Due diligence includes
both frequent assessments of suicidal ideation and hope-
lessness,aggressive treatment of the depression,and cre-
ation of a safety net involving other members of the health
care team and family members or caregivers.In the USA
and UK over the past 18 months,considerable furor has
raged about the risk that the use of one class of antide-
pressants,selective serotonin reuptake inhibitors (SSRIs)
may actually raise the likelihood of suicidal ideation and
suicidal acts, rather than reducing the likelihood.
Examination of adverse event reports for SSRIs in chil-
dren and adolescents has led to “black box warnings”in
the package inserts for SSRIs in the USA and consider-
able “official”caution in the UK about prescribing such
drugs for individuals under the age of 18.These policy
decisions have illustrated the need for better methodical
approaches for risk assessment (see below).
Phases of treatment
In developing a treatment strategy,it is useful for the clin-
ician to consider treatment of major depression as involv-
ing three phases:acute,continuation,and maintenance (if
appropriate).The goals of the acute phase are to achieve
remission (resolution of all symptoms) and restore func-
tioning (Table III).
17,18 During this period,continued fol-
low-up visits are essential.The goal of the continuation
phase is sustained remission.Unfortunately,only recently
has renewed attention been devoted to the issue of
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remission (recovery) has major adverse consequences
including the following: increased risk of relapse
19 and
treatment resistance;persistent functional impairment
20;
sustained risk of suicide;worsened morbidity of other psy-
chiatric conditions; and medical disorders. This phase
should last approximately 6 months following full remis-
sion of the acute episode.Then,the patient in whom the
risk for recurrence is low should be gradually tapered from
treatment over a period of 1 to 3 months.Rapid discon-
tinuation of virtually all antidepressants,including those
with long half-lives,tends to be associated with sympto-
matic relapse.Since the majority of depressed individu-
als suffer from recurrent depression,the physician should
consider the appropriateness of a maintenance phase.
Data on long-term treatment in the psychiatric specialty
sector indicate that maintenance treatment should be sus-
tained for a minimum of 3 to 5 years.Unfortunately,there
are no such
21-23 studies in primary care  to determine appro-
priate duration of long-term treatment in this setting.
Available medications and their use 
in acute treatment
There is no paucity of medications approved by the Food
and Drug Administration (FDA) for a depression indi-
cation.One of the two initial classes was the tricyclic anti-
depressants (TCAs),a family of structurally related com-
pounds with reuptake inhibitory properties on brain
monoamine metabolism.All the TCAs are potent block-
ers of NE reuptake (except for clomipramine which
highly serotonergic,but is approved by the FDA only for
treatment of obsessive-compulsive disorder) and weak
blockers of 5-HT reuptake.The second original class of
drugs,the monoamine oxidase inhibitors (MAOIs),have
never been widely prescribed because of real (and some-
times exaggerated) concerns about safety,despite their
established efficacy in certain subtypes,especially atypi-
cal and bipolar depression.
24,25
A majority of the newer compounds are considered to be
SSRIs. Despite a number of meta-analyses of efficacy
showing no differences between TCAs and SSRIs in
ambulatory studies,the more favorable adverse effect pro-
file (including a virtual absence of overdosage lethality),
ease of administration,and acceptance by physicians across
specialties have led to the emergence of the SSRI as first-
line treatments.
26,27 Patients can be started on the initial
dose as indicated in Table IV and gradually increased over
a 10- to 14-day period to the modal therapeutic dose.If the
patient has not responded to this dose by 3 to 4 weeks,one
should consider increasing the dose again.When the first
drug in this class is not effective,experienced clinicians will
often either try to augment the response with another
medication or switch to another SSRI.
In Table IV,the starting,modal therapeutic,and maximum
recommended doses are listed for the approved drugs by
class.Other currently approved antidepressants are avail-
able in the USA include venlafaxine,mirtazapine,bupro-
pion,trazodone,and nefazodone.While trazodone is often
used as an adjunctive medication for sleep problems asso-
ciated with depression itself or with the use of the more
alerting SSRIs,of these four drugs,only venlafaxine (with
presumed dual neuronal reuptake inhibition) has emerged
as comparable in overall use to the SSRIs.In fact,several
meta-analyses have pointed to increased efficacy when
compared with fluoxetine,but not necessarily with other
SSRIs (C.Nemeroff,personal communication).
28,29
The antidepressant market remains a highly competitive
one,with a number of pharmaceutical companies intro-
ducing compounds that they hope will prove to have faster
onset of action,produce a more complete remission,and
reduce side-effect burden,especially weight gain and sex-
The pharmacological management of depression - Kupfer Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
195
Table III. Depression medication algorithms. Contact may be in person or
by telephone.
Reproduced from Rush AJ et al (The Texas Medication Algorithm Project),
personal communication.
• Contact frequency
Weekly for the first 4 weeks of each stage, then every 2 
weeks until 75% improvement is maintained for 4 weeks
• Assessment frequency 
At each contact
• Duration of acute treatment 
At least 75% for 4 weeks, then move to continuation phase
• Response  
Nonresponse (<25% improvement)
Minimal response (25-50% improvement)
Partial response (50-75% improvement)
Full response (75-100% improvement)
Full remission (75-100% improvement sustained for 4 weeks)
• Criteria for medication change   
Anything less than 75% improvement or full response may 
require a medication change
• Evaluations    
At each contact, a nurse’s or physician’s assessment of core 
symptom severity, overall functional impairment, side-effect 
severity, and other symptomsual dysfunction.Escitalopram (the single-isomer form of
citalopram) recently received FDA approval and dulox-
etine (an SNRI [serotonin and noradrenaline uptake
inhibitor] with dual reuptake inhibition of 5-HT and NE)
has also been approved.It is also important to point out
that several antidepressant drugs approved in Europe and
Canada (eg, tianeptine, reboxetine, milnacipran, and
moclobemide) are not approved for use in the USA.
Therapeutic interest in psychostimulants has led to stud-
ies suggesting that methylphenidate is generally well tol-
erated and modestly efficacious for medically burdened
depressed elders, but should only be used in the short
term.
30 It is also appropriate to comment on the current
status of herbal remedies for depression that currently
fall outside the FDA guidelines.Although there are a
number of reports pointing to the efficacy of Hypericum
perforatum (Saint John’s wort) for major depression,
31,32
two US trials comparing Hypericum with an SSRI and
placebo have not supported this claim.
33-35
While adverse effects are reported with all antidepressant
compounds, most are transient and no major adverse
effects have been reported after long-term use.In general,
the TCAs are distinguished by anticholinergic and anti-
histamic effects (Table V).
36-41 Drug interaction with TCAs
and other medications affecting the hepatic enzyme (CYP
2D6) can lead to significantly altered TCA plasma levels.
MAOIs are used sparingly,partly because of concern with
hypertensive crises,as well as their interaction with other
prescribed medications and beer,red wine,and foodstuffs
rich in the amino acid tyramine,such as aged cheese and
liver.Clinical experiences in the last 15 years have shown
that the SSRIs are relatively safe,but their adverse effect
profile may not be the same across the entire class.While
the efficacy and adverse effect profile should be consid-
ered in selecting among the SSRIs,in usual practice these
drugs do not differ dramatically in efficacy from each
other or from the older classes of antidepressants. The
adverse effects that most frequently influence patients’
decisions to discontinue treatment are sexual dysfunction
and weight gain.In inpatient settings,TCAs are still often
used as first-line treatment.Not all SSRI (eg,citalopram
and sertraline) have a high degree of drug–drug interac-
tion via the cytochrome P450 (CYP) system.While nau-
sea, sedation, appetite change, and sexual dysfunction
seem approximately similar for the SSRI class,claims for
reduced adverse effects on sexual functioning have been
made for fluvoxamine (only approved by the FDA for
obsessive-compulsive disorder),
42 as have claims for
reduced discontinuation effects for fluoxetine.
43 Finally,
the high degree of comorbidity of depression and cigarette
consumption needs to be fully understood.Tobacco smok-
ing can induce CYP enzyme changes affecting blood lev-
els of various antidepressants,as well as complicate drug
management when smoking cessation occurs.
44
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Table IV. Currently available antidepressants and their recommended
dosages. SSRI, selective serotonin reuptake inhibitor; TCA, tri-
cyclic antidepressant; MAOI, monoamine oxidase inhibitor. *A
generic formulation is available. 
†Approved by the Food and
Drug Administration (FDA) for treatment of obsessive-compul-
sive disorder, but not depression. 
‡The higher dosage is approved
in some countries but not in the USA. 
§A maximum therapeutic
dose has not yet been established for this compound. 
||Even
higher doses might be indicated if plasma drug concentrations
are low (ie, <50 ng/mL). 
¶The maximum FDA-approved dosage
of the extended-release formulation is 225 mg/day.
Drug name Initial dose Modal  Maximum 
(mg/day) therapeutic dosage 
dose (mg/day) (mg/day)
SSRIs
• Fluoxetine* 20 20-40 60-80
• Paroxetine 20 30 50
• Sertraline 50 100 200
• Fluvoxamine*
,† 50 150 300
• Citalopram 20 30 40-60
‡
• Escitalopram 10 20 20
§
TCAs and related compounds
• Amitriptyline* 25 150 300
• Nortriptyline* 25 50-75 100-150
||
• Imipramine* 25 150 300
• Desipramine* 25 100 300
• Doxepin* 25 100 300
• Clomipramine*
,† 25 100 250
• Protriptyline 10 20-30 60
• Trimipramine* 25-50 150 300
• Amoxapine 50 150-200 400
• Malprotiline 25-50 150-225 300
Mixed norepinephrine/serotonin reuptake inhibitors
• Venlafaxine 75 150 225/375
¶
• Mirtazapine 15 30 45-60
‡
Other antidepressants
• Bupropion* 150 300 450
• Trazodone* 50 200 400-600
• Nefazodone 200 300 600
MAOIs
• Phenelzine 15 45 90
• Tranylcypromine 10 40 60
• Isocarboxazid 20 30-40 60The pharmacological management of depression - Kupfer Dialogues in Clinical Neuroscience - Vol 7 . No.3 . 2005
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Table V. Adverse effects of antidepressants.
36-41 SSRI, selective serotonin reuptake inhibitor; TCA, tricyclic antidepressant; NSRI, noradrenaline and
serotonin reuptake inhibitor; MAOI, monoamine oxidase inhibitor; AMX, amoxapine; DOX, doxepine; IMI, imipramine; PRO, protripty-
line; AMI, amitriptyline; ECIT, escitalopram; MRZ, mirtazapine; SER, sertraline; CIT, citalopram; FLVX, fluvoxamine; NOR, nortriptyline; TRY,
tranylcypromine; CLO, clomipramine; FLX, fluoxetine; PAX, paroxetine; VEN, venlafaxine; DES, desipramine; CNS, central nervous system;
GI, gastrointestinal; ECG, electrocardiogram; CAD, coronary artery disease; MI, myocardial infarction.
SSRI TCA Mixed NSRI MAOI Bupropion Trazodone Nefazodone
• Anticholinergic effects
Dry mouth Moderate: AMI, AMX, CLO, MRZ>VEN Moderate Moderate None  Moderate
Constipation PAX, FLVX PRO>DOX, DES, significant
Sweating IMI, NOR;
Urinary retention contraindicated in
glaucoma, DOX 
• CNS effects
Sedation Insomnia and AMI, CLO, DOX, Moderate  Headache Moderate High Moderate
Insomnia somnolence IMI>AMX, DES, sedation/ sedation, sedation sedation,
Headache common to all; NOR somnolence, headache headache,
Asthenia asthenia, SER, CIT; MRZ; headache, asthenia
headache, CIT asthenia, VEN
• GI effects
Nausea Nausea, diarrhea  Weight gain, Moderate weight  Moderate  Nausea,  None  Hepatic 
Weight changes common to all CLO gain, appetite  weight gain  vomiting,  significant dysfunction,
Appetite changes changes, MRZ;  or anorexia weight gain nausea
Hepatic dysfunction nausea, VEN
• Cardiovascular effects
Orthostatic None  Monitor ECG in  Hypertension,  Hypertensive  None  Syncope None 
hypotension significant patients with history  caution in  crisis; postural  significant significant
Tachycardia of CAD or high dose  elderly or  hypotension
ECG changes TCAs; better  those with 
tolerated, DES, NOR;  history of 
contraindicated in CAD with 
acute recovery of  doses
MI; orthostatic   >200 mg/day,
hypotension, IMI VEN
• Sexual dysfunction
Impotency PAX, FLX,  AMI, AMX,  Abnormal  Impotency None Priapism None
Abnormal ejaculation SER>FLVX,  CLO, DES,  ejaculation,  significant significant
Decrease libido CIT, ECIT NOR, PRO  impotency, 
Agnorgasmia VEN
• Discontinuation syndrome
Physical symptoms More  Associated more  VEN Greater  None None None
(ie, GI,  common, with physical and  propensity,  significant significant significant
sleep disturbances) PAX, SER;  psychological  TRY
Psychological symptoms less due to  symptoms
(ie, somatic, affect) longer-acting
Sensory abnormalities metabolite, FLX;
(ie, paresthesia, all three symptom
numbness) types seenDepression across the life span
While some aspects of the symptom picture may change
across the life span,the core features of depression are
recognizable.In children and adolescents,depression is
not always characterized by sadness,but instead by irri-
tability,boredom,or an inability to experience pleasure.
Depression is present in about 1% of children and 5% of
adolescents at any given time.
45 Before puberty,boys and
girls are at equal risk for depression,whereas after the
onset of puberty,the rate of depression is about twice as
high in girls.While prepubertal depression is less preva-
lent than postpubertal depression,appropriate manage-
ment at any age for major depression is recommended.
At the other end of the life span,depressed older adults
will usually be seen at medical facilities.Major depres-
sion affects 5% to 10% of older adults who visit a pri-
mary care provider
46-48 and has negative implications for
the prognosis of almost all co-occurring medical illnesses
with which such patients may present.
Treatment of child and adolescent depression
Drug treatment for children or adolescents with depres-
sion is primarily dependent on SSRIs as first-line acute
treatment.Efficacy trials have been conducted with flu-
oxetine, paroxetine, and citalopram.
49-51 The recom-
mended practice is to start at half the usual dose of an
SSRI (eg, 10 mg/day fluoxetine, paroxetine, or citalo-
pram) for 1 week for adjustment purposes and then
increase the dose to the equivalent of 20 mg/day fluox-
etine for another 3 weeks.
45 It takes up to 4 weeks at
steady state to determine whether a given dose will be
helpful.Thus,further increases should be made at 4-week
intervals.Because children and adolescents metabolize
SSRI more rapidly than adults,they often require doses
above the equivalent of 20 mg fluoxetine to attain a clin-
ical response.
52 The large National Institute of Mental
Health (NIMH) multicenter contract, Treatment for
Adolescents With Depression Study (TADS),
53 for the
treatment of depression in adolescents has been recently
completed,and perhaps will provide more definitive data
for this population.
In a sample of 439 adolescents (aged 12 to 17 years) with
major depression,four randomly assigned interventions
were utilized:fluoxetine (10 to 40 mg/day) with cognitive
behavioral therapy (CBT);fluoxetine alone;CBT alone;
and placebo.As noted in Table VI,71% responded to the
combined treatment, with 60.6% to fluoxetine alone,
43.2% to CBT alone,and 34.8% to placebo.A clinically
useful manner to review these findings is to calculate
number needed to treat (NNT;calculated as 1/risk dif-
ference). NNT represents the number of subjects who
would have to be treated with active treatment to obtain
one success that would not be obtained with the control
treatment.Referring to Table VI,NNT for the combina-
tion treatment is 3,fluoxetine alone 4,and CBT alone 12,
suggesting a medium effect size for the combination
treatment and for fluoxetine alone.In addition,clinically
significant suicidal thinking present in 29% of the sam-
ple at baseline improved significantly.Seven (1.6%) of
439 patients attempted suicide,but there were no com-
pleted suicides.
Treatment of geriatric depression
In a similar fashion, SSRIs have now largely replaced
TCAs and MAOIs as first-line acute treatments for late-
life depression.
54 SSRIs are administered in older patients
with initial dosing at half the usual effective dose and
doubled after 1 week.A recent review has concluded that
SSRIs are efficacious, safe, and well tolerated in older
patients with depression without comorbidity,as well as
in those with medical comorbidity,
55 including dementia,
56-60
cardiovascular disease,
61 cerebrovascular disease,
62
stroke,
63,64 and other medical conditions.
65-69
Although most data are supportive of SSRIs as a class in
the treatment of geriatric depression,experts favor the
use of citalopram or sertraline over fluvoxamine and flu-
oxetine
54,70 because of their favorable pharmacokinetic
profiles, a lower potential for clinically significant
drug–drug interaction,and data suggesting their superi-
ority in terms of cognitive improvement.
57,58,71,72 One
placebo-controlled study with sertraline in elderly out-
patients with major depression treated in both psychiatric
and primary care settings further supports use of SSRIs
in geriatric depression.
73 In the “old-old”population (≥75
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Table VI. Treatment for Adolescents with Depression Study (TADS) ran-
domized controlled trial.
53 NNT, number needed to treat; CBT,
cognitive behavioral therapy.
Treatment Rate of response NNT Effect size
Fluoxetine with CBT 71% 3 0.84
Fluoxetine alone 60.6% 4 0.58
CBT alone 43.2% 12 0.20
Placebo 34.8% – –years old) with depression, active medication (citalo-
pram) was no more effective than placebo, except for
patients with high levels of baseline severity.
74Among the
TCAs,where cardiac monitoring is recommended,nor-
triptyline is the most frequently used agent in the elderly,
probably because it is considered the least cardiotoxic
drug in this class and blood levels can be monitored.
Adverse drug reactions increase dramatically in fre-
quency and severity with advanced age.
75 Factors that
may influence proper dosing include the different phar-
macokinetic properties of antidepressants in elderly
compared with younger patients and individual patient
characteristics,such as cardiovascular or renal function.
In elderly patients,antidepressant side effects of partic-
ular concern include orthostatic hypotension and anti-
cholinergic effects (more common with TCAs),as well as
extrapyramidal symptoms, and the syndrome of inap-
propriate antidiuretic hormone secretion.
Course of treatment
While it used to be assumed that the typical major
depression was self-limiting (of 3 to 6 months duration)
and associated with complete recovery,the present view
is not as sanguine.Clinical trials have demonstrated that
30% to 40% of depressed patients fail to respond to first-
line antidepressant treatment despite adequate adher-
ence,dose,and duration,
76,77 60% to 70% fail to achieve a
complete remission of symptoms,
78 up to 20% have not
recovered 2 years after initiation of treatment,
79,80 and
10% remain depressed despite multiple interventions.
76,81
Many patients suffer from recurrent depression that
requires long-term maintenance treatment to prevent
future episodes of depression.Some depressive  condi-
tions,including psychotic depression,bipolar depression,
and depression with psychiatric or medical comorbidity,
have been associated with poor outcome and/or a higher
degree of resistance to specific types of treatment or to
treatment in general.
82
Successful treatment of major depression may require
more than one drug trial.A full discussion of the tactics
involved in selection of the second treatment (same
class,different class),choice of whether to augment the
first drug with a second compound or with psychother-
apy or to change treatment completely is beyond the
scope of this review.Clinicians who wish to treat rather
than refer these or complex patients can consult the
treatment algorithms derived from the Texas Medical
Algorithm Project (TMAP).
18 The goal of treatment is
full remission of symptoms,but less than 50% of patients
achieve this goal within 8 to 12 weeks. In general, if a
patient has not shown marked improvement within 8
weeks,psychiatric consultation is recommended.Clearer
guidelines for treatment augmentation and switching
should be derived from the ongoing multisite NIMH
contract, Sequenced Treatment Alternative to Relieve
Depression (STAR*D).
83 This large multicenter trial
(ultimately enrolling more than 4000 patients nation-
wide) is prospectively evaluating alternative antide-
pressants and augmentation strategies for patients at
three stages of treatment resistance.
Psychotic depression
Psychotic depression, representing over 15% of more
severely depressed cases,
84 is characterized by the pres-
ence of either delusions or hallucinations,which are often
but not always congruent with the depressive themes.
Psychotic depression has less than one half the likelihood
of responding to antidepressant monotherapy compared
with a nonpsychotic depressive disorder.
85-88
Initially,TCAs,especially in the higher dose range,were
used. Subsequent investigations indicated that TCAs
combined with typical antipsychotics provided greater
levels of efficacy (eg,amitriptyline and perphenazine).
88
Although SSRIs alone have not been used routinely to
treat psychotic depression, the use of an SSRI and an
atypical antipsychotic has shown efficacy greater than an
SSRI alone.
89 C-1073 (mifepristone), a selective gluco-
corticoid receptor II (GRII) antagonist (not currently on
the US market), has shown some promise in the acute
treatment phase of psychotic depression.
90 In urgent sit-
uations or when other treatments have failed, electro-
convulsive treatment (ECT) is warranted.While ECT is
efficacious (for psychotic depression),it has many draw-
backs including the requirement that the treatment must
be administered under anesthesia in a hospital setting or
a similarly equipped ambulatory setting.
91
Bipolar depression
Bipolar depression (major depression in patients also
experiencing periods of mania or hypomania) represents
a major challenge to clinicians,since response to treat-
ment is often poor and the process of achieving complete
remission without a switch into mania is challenging.
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stabilizers.A number of investigators have pointed to the
relatively poor response to traditional TCAs in this pop-
ulation.
92-94 Most SSRIs demonstrate only moderate suc-
cess.Recently,efforts to combine an SSRI with an atyp-
ical antipsychotic
95 have shown promising results in
bipolar depression.
96A number of atypical antipsychotic
drugs are also showing some degree of antidepressant
effect,perhaps similar to that of lithium.
The usual strategy is to use mood stabilizer monotherapy
as the first-line therapy for bipolar depression,with the
addition of an antidepressant reserved for depressed
patients who do not benefit from mood stabilizer
monotherapy.One hierarchy of mood stabilizer options
is:(i) lithium carbonate;(ii) divalproex;(iii) olanzapine
(now FDA-approved for mania and maintenance in
bipolar disorder);and (iv) lamotrigine (FDA-approved
for maintenance in bipolar disorder).
95,97,98The particular
medication is chosen on the basis of the patient’s history;
patients known to not have responded to one monother-
apy should be advanced to the next strategy.A minimum
adequate trial is 4 weeks of mood stabilizer monother-
apy at an optimal dose/blood level.
In contrast to the treatment of mania,pharmacological
treatment of bipolar depression remains vastly under-
studied.Although two important placebo-controlled tri-
als were concluded recently,
99,100 they are the first two ade-
quately powered studies ever conducted on this
condition. Despite the severity of pediatric bipolar
depression,empirical data on its treatment are limited,
largely because of the relatively low prevalence of pedi-
atric bipolar disorder.The SSRIs are the only class of
medications with some level of proven efficacy in pedi-
atric unipolar depression.
49,101,102 Practitioners are com-
pelled to treat depressed bipolar children and adoles-
cents using the SSRI because the illness is so severe;
however,the SSRI sometimes worsen the cyclicity of the
disorder.We also lack any controlled treatment studies
of bipolar depression in later life.
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Comorbidity
Comorbidity or “co-occurrence”of either other psychi-
atric disorders or medical disorders is very common in
major depression.Indeed,it is so common that the fre-
quent questions raised include the heterogeneity of the
depressive disorder,subgroups with specific comorbidi-
ties,and whether such nosological differences have treat-
ment and/or pathophysiological implications.
5 For exam-
ple,bipolar depression is associated often with panic-anx-
iety features,substance use,and cardiovascular disease,
all of which have effects on immediate and long-term
prognostic indicators.
Comorbidity of substance and alcohol abuse with
depression is  generally associated with a worse prog-
nosis.
104 Several symptoms of alcohol and substance
abuse, such as sleep disturbance, irritability, and dys-
phoria,contribute to this outcome.In fact,even moder-
ate use of psychoactive substances such as alcohol can
have a negative effect on the outcome of treatment for
major depression and should be discouraged until the
depression is fully remitted.
105 The frequent association
of substance abuse with other comorbid disorders (eg,
antisocial personality or anxiety disorders) may further
complicate the prognosis.
106
Medical co-occurrence represents another major factor
contributing to poor treatment response.Diseases like
hypothyroidism,stroke,diabetes,coronary artery disease,
Parkinson’s disease, human immunodeficiency viral
infection and acquired immunodeficiency syndrome,can-
cer,and chronic pain syndrome can play a major role in
reducing treatment responsiveness,especially when the
medical illness is irreversible.
107 Even when a reversible
underlying medical condition is contributing to depres-
sion,treatment of that condition alone is not always suf-
ficient to resolve the depression.Furthermore,some of
the medications used to treat comorbid medical condi-
tions may induce or worsen a depressive episode.
Depression is a risk factor for mortality after acute
myocardial infarction (MI) and a morbidity risk factor
associated with slow recovery from an MI and poorer
quality of life.
108-111 Recent trials with SSRIs are pointing
to these medications as safe and effective treatment for
recurrent depression with recent MI or unstable angina,
although a beneficial effect on the underlying cardiac dis-
ease has not been found consistently in studies to
date.
112,113 It is likely that similar findings will emerge
from intervention studies in depression and other con-
current serious medical conditions.
Continuation/maintenance treatment
Clinical guidelines generally recommend that treatment
should be continued for at least 6 months following
remission of acute symptoms.
114,115 However,because of
the recurrent nature of depressive disorder,a question is
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antidepressant medication.A recent review of data from
longer-term studies
116 pooling 31 randomized trials,
demonstrated that continuing treatment reduced the
odds of relapse by 70% (95% confidence interval [CI]
62% to 78%) compared to treatment discontinuation.
The average rate of relapse or recurrence on placebo was
41% compared with 18% on active treatment.Most of
the trials were of only 12 months’ duration.Thus,the evi-
dence on longer-term treatment requires confirmation;
however, in the longer trials evaluated, the treatment
effect appeared to persist for up to 36 months.
This new analysis reinforces the available  findings from
long-term maintenance trials conducted with TCA.The
Prien et al
21 and Frank et al
22 maintenance studies with
imipramine in mid-life adults,followed by the Reynolds
et al
23 study in late-life depression with nortriptyline,
established the efficacy of long-term maintenance treat-
ment with antidepressants,specifically in recurrent major
depression.Subsequent studies with SSRIs have pointed
to similar levels of efficacy with fluoxetine,sertraline,and
citalopram in mid-life patients and with citalopram in
late-life patients,most of whom had experienced at least
one prior episode of depression.
117-120 Furthermore,stud-
ies on long-term treatment of chronic depression (major
depression with an episode lasting greater than 2 years)
with the TCAs, desipramine and imipramine, and the
SSRI,sertraline,have demonstrated efficacy in chronic
depression.
121,122
While this report is not focused on psychotherapy for
treatment of depression,it is noteworthy that the combi-
nation of antidepressants and specific targeted psy-
chotherapy (interpersonal psychotherapy) has been con-
ducted successfully in long-term trials with some
suggestion in the elderly that combination treatment was
better than antidepressants alone.
22,23
Future directions and conclusions
As discussed earlier in this review on the section on
pathogenesis and drug targets,considerable efforts are
being directed toward the development of new strategies
for drug discovery in depression.These strategies include,
as highlighted by Nestler et al
123“developing better ani-
mal models of mood disorders;identifying genetic deter-
minants of normal and abnormal mood in humans and
animals; discovering novel targets and biomarkers of
mood disorders and treatments.”
Biomarkers for depression have traditionally been divided
into four groups
8:peripheral,CNS neurochemical,CNS
functional, and genetic biomarkers. Recent advances in
functional and positron emission tomography (PET) neu-
roimaging,as well as pharmacogenetics,have overshad-
owed the previous primacy of peripheral markers. The
advantages of these new methodologies are numerous,
such as more direct CNS determinations, the ability to
combine modalities such as cognitive neuroscience para-
digms and functional magnetic resonance imaging (fMRI),
and repeatability of measures over extended periods of
time. However, the current limitations including ligand
development,better pharmacogenetic tactics,and appro-
priate recruitment of large sample sizes may limit the
extent of the immediate payoff for such strategies.
One final concern in the overall positive picture for
advances in therapeutics for depression has been our fail-
ure to utilize the best available methodological tools to
design and interpret clinical trials in depression.
Insufficient planning for sample size,target population,
appropriate outcome measures,multisite “assessment,”
and direct tactical planning for placebo effects have been
associated on total focus on statistical significance,with
less focus on clinical significance.Our failure to articu-
late clinical significance and effect size,as specified with
the use of effect size determinations,is partially respon-
sible for our weak clinical trial design strategies. Risk
assessment for clinical trials to utilize tactics such as NNT
for benefit (efficacy) and NNH (number needed to
harm) for adverse events (risk) ratio should be con-
ducted in all clinical trials and should be reported rou-
tinely. More attention should be given to moderator
mediator analyses to identify important therapeutically
responsive subgroups.
124 In summary,all the contempo-
rary biostatistical methodological tools should be aligned
with the neuroscience and genetic toolbox to increase the
likelihood that newer treatments for depression will be
developed in the near future. ❏
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El manejo farmacológico de la depresión
Los trastornos depresivos se caracterizan por ser
comunes, recurrentes, crónicos y requerir trata-
miento. Una revisión del cuadro clínico y de los fár-
macos actualmente disponibles demuestra la necesi-
dad de una acuciosa evaluación de la gravedad de la
depresión, incluyendo el riesgo suicida. El foco inicial
del tratamiento se centra en la resolución rápida de
los síntomas durante la fase aguda, a lo que debe
seguir la fase de continuación. El tratamiento de
mantención se indicará cuando el riesgo de recu-
rrencia sea alto. La cantidad de medicamentos dis-
ponibles es considerable y la relación riesgo/benefi-
cio es aceptable. La depresión se puede diagnosticar
a lo largo de toda la vida y tratar en cada edad (aun-
que recientemente han surgido algunos desacuerdos
en relación a los pacientes más jóvenes). También
debe ser evaluada la comorbilidad, tanto psiquiátrica
como médica, al igual que la posible presencia de
dos de los subtipos de depresión (psicótica y bipolar)
ya que habitualmente requieren de intervenciones
diferentes. Se espera que la próxima generación de
antidepresivos se asocie con enfermedades y con
marcadores biológicos de evolución mas específicas. 
La prise en charge pharmacologique de la
dépression
Les troubles dépressifs sont courants, récurrents,
chroniques et nécessitent un traitement. Une
revue de la symptomatologie et des cibles médi-
camenteuses actuelles met en évidence un besoin
d’évaluation exacte de la sévérité de la dépression,
« suicidalité » incluse. Le but initial du traitement
est la résolution rapide des symptômes pendant la
phase aiguë, et sa poursuite. Le traitement d’en-
tretien est indiqué si le risque de récidive est
élevé. La gamme de médicaments disponibles est
très importante et le rapport bénéfice/risque est
acceptable. La dépression peut être diagnostiquée
tout au long de la vie et traitée quel que soit l’âge
(malgré des désaccords récents concernant les
patients jeunes). La comorbidité, à la fois psychia-
trique et médicale, doit être évaluée comme doit
l’être la présence éventuelle de deux sous-types de
dépression (psychotique et bipolaire) pour lesquels
les besoins thérapeutiques sont souvent différents.
On espère que la nouvelle génération d’antidé-
presseurs s’adressera à des troubles plus spéci-
fiques et comportera des biomarqueurs de résul-
tats.
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